Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | GLA | P06280 | 1/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.63 |
| ▸ | ST6GAL1 | P15907 | 9/20 | 0.59 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citicoline SCHEMBL31554836 | 1.00 | TSHR (0.73) | TSHRGLAP2RY2ST6GAL1P2RY6 | |
| Citicoline SCHEMBL31413926 | 1.00 | TSHR (0.73) | TSHRGLAP2RY2ST6GAL1P2RY6 | |
| Citicoline SCHEMBL221081 | 1.00 | TSHR (0.73) | TSHRGLAP2RY2ST6GAL1P2RY6 | |
| Citicoline SCHEMBL19347200 | 0.99 | TSHR (0.72) | TSHRGLAP2RY2ST6GAL1P2RY6 | |
| Citicoline SCHEMBL21906414 | 0.98 | TSHR (0.70) | TSHRGLAP2RY2ST6GAL1P2RY6 | |
| Citicoline SCHEMBL25411862 | 0.97 | TSHR (0.76) | TSHRGLAP2RY2ST6GAL1P2RY6 | |
| Citicoline SCHEMBL4311534 | 0.97 | TSHR (0.76) | TSHRGLAP2RY2ST6GAL1P2RY6 | |
| Citicoline SCHEMBL667104 | 0.93 | TSHR (0.84) | TSHRGLAP2RY2ST6GAL1P2RY6 | |
| Citicoline SCHEMBL14235352 | 0.93 | P2RY2 (0.70) | TSHRGLAP2RY2ST6GAL1P2RY6 | |
| Citicoline SCHEMBL13933086 | 0.93 | P2RY2 (0.70) | TSHRGLAP2RY2ST6GAL1P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11330 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077548-A2 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | Celgene Corporation (US) | 2016-10-12 | — | — | EP | claimed |
| CN-103279127-B | A kind of only by the GEO orbiter Autonomous Control method of angle information | 上海新跃仪表厂 | 2016-06-22 | — | — | CN | claimed |
| WO-2015085172-A2 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | CELGENE CORPORATION (US) | 2015-06-11 | — | — | WO | claimed |
| EP-1858926-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | Halozyme Therapeutics, Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| EP-1740107-A1 | ELECTROMAGNETIC TREATMENT APPARATUS AND METHOD | IVIVI Technologies, Inc. (US) | 2007-01-10 | — | — | EP | claimed |
| WO-2006091871-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | HALOZYME THERAPEUTICS, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| WO-2005102188-A1 | ELECTROMAGNETIC TREATMENT APPARATUS AND METHOD | IVIVI TECHNOLOGIES, INC. (US) | 2005-11-03 | — | — | WO | claimed |
| JP-1313467-A | — | — | None | — | — | JP | disclosed |
| US-12629533-B2 | System and method for precision dosing for electrical stimulation of the brain | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2026099243-A1 | MODIFIED AND UNMODIFIED PEPTIDYL-GLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN THE TREATMENT OR PREVENTION OF CEREBRAL HYPOPERFUSION FOR THE IMPROVEMENT OF CEREBRAL BLOOD FLOW (CBF) | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | disclosed |
| EP-4741014-A2 | DIAGNOSIS OF DEMENTIA BY VASCULAR MAGNETIC RESONANCE IMAGING | Northeastern University (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12623047-B2 | Device, method, and app for facilitating sleep | NeuroLight, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-0229644-A2 | Method of use for diltiazem, verapamil or nifedipine having activity for the treatment of stroke | WARNER-LAMBERT COMPANY (US) | 1987-07-22 | — | — | EP | disclosed |
| US-4654372-A | ALSO NIFEDIPINE AND DILTIAZEM | WARNER-LAMBERT COMPANY (US) | 1987-03-31 | — | — | US | disclosed |
| US-4615876-A | IMAGING BY SCINTILLATION SCANNING | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1986-10-07 | — | — | US | disclosed |
| US-4489052-A | ADMINISTERING 1-(D-ARABINOFURANOSYL)PYRIMIDINE NUCLEOSIDE AND SCANNING | SLOAN-KETTERING FOR CANCER RESEARCH (US) | 1984-12-18 | — | — | US | disclosed |
| US-4263255-A | RECEPTOR BINDING KIT FOR ENKEPHALINS | BURROUGHS WELLCOME CO. (US) | 1981-04-21 | — | — | US | disclosed |
| US-4257773-A | COMPETITIVE BINDING OF ENKEPHALINS TO RECEPTORS | BURROUGHS WELLCOME CO. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4231923-A | NARCOTICS, OLIGOPEPTIDES, RADIOACTIVITY | BURROUGHS WELLCOME CO. (US) | 1980-11-04 | — | — | US | disclosed |